Zymeworks Inc. (NYSE:ZYME - Free Report) - Analysts at Leerink Partnrs dropped their Q4 2024 EPS estimates for Zymeworks in a report issued on Thursday, November 7th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of $0.70 for the quarter, down from their prior estimate of $0.86. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Zymeworks' current full-year earnings is ($1.05) per share.
Zymeworks (NYSE:ZYME - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm had revenue of $16.00 million for the quarter, compared to the consensus estimate of $17.90 million. During the same period last year, the firm earned ($0.41) earnings per share. The company's quarterly revenue was down 3.1% on a year-over-year basis.
A number of other research firms have also recently commented on ZYME. Leerink Partners raised shares of Zymeworks from a "market perform" rating to an "outperform" rating and increased their target price for the company from $10.00 to $25.00 in a research report on Thursday. Citigroup increased their target price on shares of Zymeworks from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Monday. Wells Fargo & Company cut shares of Zymeworks from an "overweight" rating to an "equal weight" rating and set a $12.00 target price for the company. in a research report on Friday, November 1st. Stifel Nicolaus raised their price target on shares of Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $12.00 price target on shares of Zymeworks in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zymeworks currently has a consensus rating of "Moderate Buy" and an average price target of $19.00.
Get Our Latest Research Report on ZYME
Zymeworks Stock Performance
NYSE:ZYME traded down $0.14 during midday trading on Friday, reaching $16.63. 678,739 shares of the stock traded hands, compared to its average volume of 627,263. Zymeworks has a 12-month low of $6.83 and a 12-month high of $17.26. The business has a 50-day moving average of $12.90 and a two-hundred day moving average of $10.64. The stock has a market capitalization of $1.15 billion, a PE ratio of -11.18 and a beta of 1.16.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP raised its holdings in shares of Zymeworks by 12.7% during the second quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company's stock worth $33,336,000 after purchasing an additional 441,947 shares during the last quarter. Vanguard Group Inc. grew its position in Zymeworks by 2.6% during the first quarter. Vanguard Group Inc. now owns 2,458,105 shares of the company's stock valued at $25,859,000 after buying an additional 63,393 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Zymeworks by 1.2% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,930,887 shares of the company's stock valued at $16,431,000 after buying an additional 23,173 shares during the period. Perceptive Advisors LLC grew its position in Zymeworks by 55.2% during the second quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company's stock valued at $14,192,000 after buying an additional 592,904 shares during the period. Finally, Acadian Asset Management LLC grew its position in Zymeworks by 4.1% during the first quarter. Acadian Asset Management LLC now owns 1,305,057 shares of the company's stock valued at $13,724,000 after buying an additional 51,036 shares during the period. Hedge funds and other institutional investors own 92.89% of the company's stock.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Further Reading
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
